COOHealthcare · Medical Instruments & SuppliesThe 17 Wall Street analysts covering The Cooper Cos., Inc. hold a median 12-month price target of $65 — +8.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 26 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores The Cooper Cos., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Momentum (37): The shares have been drifting down relative to others.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on COO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.6% from it.
Of the 20 most recent actions, 0 moved their price target up and 9 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $60 |
| 15 Sept 2026 | Needham | Reiterates | Buy | $73 |
| 15 Sept 2026 | Needham | Reiterates | Buy | — |
| 11 Sept 2026 | Mizuho | Maintains | Outperform | — |
| 11 Sept 2026 | Mizuho | Maintains | Outperform | $85 → $75 |
| 10 Sept 2026 | B of A Securities | Downgrade | Neutral | — |
| 10 Sept 2026 | B of A Securities | Downgrade | Neutral | $80 → $65 |
| 10 Sept 2026 | Baird | Downgrade | Neutral | — |
| 10 Sept 2026 | Baird | Downgrade | Neutral | $85 → $61 |
| 10 Sept 2026 | Citigroup | Maintains | Neutral | — |
| 10 Sept 2026 | Citigroup | Maintains | Neutral | $80 → $60 |
| 10 Sept 2026 | JP Morgan | Maintains | Neutral | $71 → $58 |
| 10 Sept 2026 | JP Morgan | Maintains | Neutral | — |
| 10 Sept 2026 | Needham | Maintains | Buy | — |
| 10 Sept 2026 | Needham | Maintains | Buy | $86 → $73 |
| 10 Sept 2026 | Piper Sandler | Downgrade | Neutral | $86 → $59 |
| 10 Sept 2026 | Piper Sandler | Downgrade | Neutral | — |
| 10 Sept 2026 | Stifel | Maintains | Buy | — |
| 10 Sept 2026 | Stifel | Maintains | Buy | $85 → $70 |
| 10 Sept 2026 | UBS | Maintains | Neutral | $75 → $66 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
COO appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, The Cooper Cos., Inc. returned −17.8% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 36% of US stocks
Cheaper than 43% of US stocks
Cheaper than 56% of US stocks
Cheaper than 22% of US stocks
Higher than 29% of US stocks
Higher than 93% of US stocks
Higher than 80% of US stocks
Higher than 80% of US stocks
Higher than 76% of US stocks
Higher than 56% of US stocks
Higher than 64% of US stocks
Higher than 63% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
The Cooper Cos., Inc. has a market value of $11.6B and an enterprise value of $14.3B.
Revenue in the twelve months to 31 July 2026: $4.2B. The latest quarter grew 0.6% year on year.
Net income over the same four quarters: $570.3M, a 13.5% net margin.
Diluted earnings per share, trailing twelve months: $2.93.
Free cash flow in the twelve months to 31 July 2026: $678.0M.
The Cooper Cos., Inc. spent $644.0M on share buybacks in the twelve months to 31 July 2026.
Trailing P/E: 21.0×; forward P/E: 13.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.10%, paying out 0% of earnings.
The Cooper Cos., Inc. employs 15,000 people — $282K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own The Cooper Cos., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CooperCompanies announced a leadership transition and board refreshment. Independent Director and healthcare executive Walt Rosebrough was elected Executive Chair, and the company is searching for a CEO.
Why it matters — COO watchers may want to follow the leadership transition and the ongoing CEO search.
The 17 Wall Street analysts covering The Cooper Cos., Inc. have a median 12-month price target of $65, with estimates ranging from $58 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering The Cooper Cos., Inc., 5 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Cooper Cos., Inc. 70 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, The Cooper Cos., Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +8.6% from the last close, and Ticker Nerd's factor model ranks The Cooper Cos., Inc. 70 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Cooper Cos., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $58 to $75 over the next 12 months.
The Cooper Cos., Inc. returned -17.8% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
The Cooper Companies, Inc. is a global medical device company focused on vision care and women’s health.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "CooperCompanies Announces Leadership Transition and Board Refreshment". CooperCompanies announced a leadership transition and board refreshment. Independent Director and healthcare executive Walt Rosebrough was elected Executive Chair, and the company is searching for a CEO.
The Cooper Companies, Inc. is a global medical device company focused on vision care and women’s health. Through its CooperVision segment, the company develops, manufactures, and markets a broad range of contact lenses, including daily disposable, toric, multifocal, and specialty products designed to support different vision correction needs. Its CooperSurgical segment provides fertility, reproductive health, and women’s healthcare products and services, including medical devices, diagnostic tools, cryostorage solutions, and office-based surgical products. The Cooper Companies serves eye care professionals, fertility clinics, hospitals, and other healthcare providers across international markets. Headquartered in San Ramon, California, The Cooper Companies, Inc. plays an important role in specialized healthcare by combining consumer-facing vision products with clinical solutions for reproductive and women’s health.
CEO Mr. Albert G. White III · 15,000 employees · United States · https://www.coopercos.com
